NJ Stock: What to Know Before the Bell on November 10, 2025 (Fresh FDA Wins, Dividend Date, and Legal Overhang)
Dateline: Monday, November 10, 2025 — pre‑market Johnson & Johnson (NYSE: JNJ) starts the new week with momentum from multiple drug approvals, a firm dividend timetable, and a still‑active litigation backdrop. Here’s a concise, investor‑focused briefing on the key developments likely to guide JNJ sentiment before the U.S. market opens today. Key takeaways• Q3 beat and higher 2025 sales outlook; adjusted EPS guidance reaffirmed. JNJ.com+1• Two fresh FDA wins in the past few weeks: Caplyta add‑on use in depression and Darzalex Faspro for high‑risk smoldering myeloma. Reuters+1• Inlexzo bladder‑cancer device approval broadens 2025 product catalysts. U.S. Food and Drug Administration•
